Lifesign 39025 - Status BTA Test, 25 Tests
Status BTA Test
A Rapid Test For the Qualitative Detection of Bladder Tumor Associated Antigen in Human Urine
- CLIA Waived
- Indicated for the use as an aid in the monitoring of bladder cancer patients in conjunction with cystoscopy
- Simple procedure
- Accurate test results with superior sensitivity and specificity
A Rapid Test For the Qualitative Detection of Bladder Tumor Associated Antigen in Human Urine of Patients Diagnosed with Bladder Cancer
Tumor markers are substances found in the blood, urine, stool, other body fluids, or tissues of some cancer patients. Tumor markers may be used to help diagnose cancer, predict a patients response to certain cancer therapies, check a patients response to treatment, or determine whether cancer has returned3. Because tumor markers can be used to assess the response of a tumor to treatment and for prognosis, rapid screening tests like the Status BTA product are very helpful in the treatment management of cancer patients.
The Status BTA test is an in vitro immunoassay intended for the qualitative detection of bladder tumor associated antigen in urine of persons diagnosed with bladder cancer. The test is indicated for use as an aid in the management of bladder cancer patients in conjunction with cystoscopy. The simple urine sample collection also allows for improved patient comfort. Patients with previous diagnosis of bladder cancer have been routinely followed for recurrence by urine cytology and cystoscopy but both methods have their limitations.
